They found a significant reduction in LAL activity in NAFLD patients and the enzyme activity was significantly worse in the subgroup of patients with biopsy-proven non-alcoholic steatohepatitis (NASH). Here, LIPA is linked to metabolic dysfunction-associated steatotic liver disease.